Is the sleeping giant finally starting to stir?

ICER adds a more formal process to evaluate the diversity of clinical trials and an assessment of a product’s impact on patient and caregiver productivity. ICER also plans to evaluate how newer methods — which would consider the change of a drug’s price over time and disease severity — can be applied to its value assessment.

Managed Healthcare Executive's Managing Editor Peter Wehrwein, and Editor Briana Contreras, had a discussion in July with Mostafa Kamal, president and CEO of Prime Therapeutics, an organization in which Kamal acquired this position that same month.

Goldsack also explained the Digital Medicine Society’s role as a convener and developer of evidentiary frameworks in a recent interview with Managed Healthcare Executive.

Briana Contreras, an editor of Managed Healthcare Executive, had the pleasure of catching up with MHE Editorial Advisory Board Member, Ateev Mehrotra, MD, MPH, who is a professor of healthcare policy at Harvard Medical School and an Associate Professor of Medicine and Hospitalist at Beth Israel Deaconess Medical Center.

Two possibly curative gene therapies for the disease, which disproportionately affects Black people, are under consideration by the FDA.

Audits and AI might help deal with the problem of woefully inaccurate provider directories supplied by insurers to their members.